Rituximab for interstitial pneumonia with autoimmune features at two medical centres.

Kristin M D'SilvaIazsmin Bauer VenturaMarcy B BolsterFlavia V CastelinoAmita SharmaBrent P LittleAyodeji AdegunsoyeMary E StrekHyon ChoiSydney B Montesi

Published in: Rheumatology advances in practice (2021)

In patients with IPAF treated with RTX at two medical centres, the majority (40 [80%]) demonstrated improvement/stability at 1 year. These findings call for prospective studies, including randomized clinical trials, to determine the risks, benefits and cost effectiveness of RTX in IPAF.

Keyphrases

healthcare
diffuse large b cell lymphoma
multiple sclerosis
clinical trial
risk assessment
case control
intensive care unit
acute respiratory distress syndrome